151 |
ADRENOCEPTOR ALPHA 2B |
ADRA2B |
ADRA2L1 |
ADRA2RL1 |
ADRARL1 |
ALPHA2BAR |
FAME2 |
alpha-2BAR |
104260 |
282 |
ENSG00000274286 |
OTTHUMG00000188276 |
ENSG00000181210 |
ALPHA-2B ADRENERGIC RECEPTOR (ALPHA-2B ADRENOCEPTOR) (ALPHA-2B ADRENORECEPTOR) (SUBTYPE C2). [SOURCE:UNIPROT/SWISSPROT;ACC:P18089] |
BE0000572 |
P18089 |
ADA2B_HUMAN |
ENSG00000222040 |
ALPHA-2B ADRENERGIC RECEPTOR |
Alpha-2B adrenoceptor |
Alpha-2B adrenoreceptor |
Alpha-2 adrenergic receptor subtype C2 |
26 |
α<sub>2B</sub>-adrenoceptor |
NP_000673 |
NM_000682 |
PA36 |
Adrenergic receptor alpha-2B |
T41580 |
Human Readable Name | DRUGGABLE GENOME |
Transmembrane Helix Count | 7 |
Target Subclass | Rhodopsin |
Target Subclass | GPCR |
Target Main Class | Receptors |
Uniprot Status | Swiss-Prot |
Interpro Short Name | 7TM_GPCR_Rhodpsn |
Human Readable Name | G PROTEIN COUPLED RECEPTOR |
Interpro Acc | IPR000276 |
Uniprot Evidence | 2: Evidence at transcript level |
Interpro Type | Family |
Interpro Name | GPCR, rhodopsin-like, 7TM |
GuideToPharmacology Gene Category Name | Adrenoceptors |
GuideToPharmacology Gene Category ID | 4 |
Target Class | Receptors |
Gene Biotype | PROTEIN_CODING |
CELL SURFACE |
G PROTEIN COUPLED RECEPTOR |
DRUGGABLE GENOME |
agonist (activating) |
binder |
Specific Action of the Ligand | Agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
binder |
antagonist (inhibitory) |
Details of the Assay for Interaction | Inhibition of agonist-stimulated [<sup>35</sup>S]GTPγS binding |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
binder |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Full agonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
n/a |
Novel drug target | Established target |
Trial Name | fipamezole, JP-1730 |
agonist (activating) |
Details of the Assay for Interaction | Calculated from [<sup>3</sup>H]RS-79948-197 radioligand competition binding to membrane preparations from CHO cells expressing human α<sub>2B</sub>-AR. |
Specific Action of the Ligand | Agonist |
Endogenous Drug? | False |
agonist (activating) |
Trial Name | NVD-422, tizanidine oral spray |
Novel drug target | Established target |
Trial Name | tizanidine hydrochloride,Zanaflex |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
binder |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Trial Name | transdermal lidocaine/epinephrine patch,Lidosite |
Novel drug target | Established target |
Mechanism of Interaction | Adrenergic receptor agonist |
agonist (activating) |
Novel drug target | Established target |
Trial Name | - |
n/a |
Trial Name | - |
Novel drug target | Established target |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
n/a |
Trial Name | - |
Novel drug target | Established target |
antagonist (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
other/unknown |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha-2 antagonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha agonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha agonist |
Direct Interaction | yes |
n/a |
Trial Name | AGN-214868 |
Novel drug target | Established target |
agonist (activating) |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Trial Name | low dose intravenous methamphetamine |
Novel drug target | Established target |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Novel drug target | Established target |
Trial Name | Asenapine |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
Direct Interaction? | True |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
agonist (activating) |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Mechanism of Interaction | Adrenergic receptor antagonist |
Direct Interaction | yes |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor alpha antagonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor agonist |
Direct Interaction | yes |
antagonist (inhibitory) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Direct Interaction | yes |
Mechanism of Interaction | Adrenergic receptor agonist |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Direct Interaction? | False |
antagonist (inhibitory) |
antagonist (inhibitory) |
Trial Name | ALKS 3831 |
Trial Name | OREX-003, olanzapine plus zonisamide SR |
Trial Name | Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Mechanism of Interaction | Adrenergic receptor alpha-2 agonist |
Direct Interaction | yes |
ADRA2B | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ADA2B_HUMAN | Uniprot Id |
ALPHA-2B ADRENERGIC RECEPTOR | Uniprot Protein Name |
ADRA2B | Uniprot Gene Name |
Uniprot Status | Swiss-Prot |
Interpro Short Name | 7TM_GPCR_Rhodpsn |
Human Readable Name | G PROTEIN COUPLED RECEPTOR |
G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME |
ADRA2B | Gene Symbol |
Target Class | Receptors |
Target Subclass | GPCR |
Target Subclass | Rhodopsin |
ENSG00000181210 | Ensembl Gene Id |
ALPHA-2B ADRENERGIC RECEPTOR (ALPHA-2B ADRENOCEPTOR) (ALPHA-2B ADRENORECEPTOR) (SUBTYPE C2). [SOURCE:UNIPROT/SWISSPROT;ACC:P18089] | Description |
ADRA2B | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
ADA2B_HUMAN | Uniprot Id |
ENSG00000222040 | Ensembl Gene Id |
ADRA2B | Gene Symbol |
Transmembrane Helix Count | 7 |
Target Subclass | Rhodopsin |
Target Subclass | GPCR |
282 | HUGO Gene ID |
282 | HUGO Gene Symbol |
adrenoceptor alpha 2B | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Adrenoceptors |
GuideToPharmacology Gene Category ID | 4 |
G PROTEIN COUPLED RECEPTOR |
ADRA2B | DrugBank Gene Name |
P18089 | UniProt Accession |
151 | Entrez Gene Id |
ENSG00000222040 | Gene Symbol |
ADRA2B | Ensembl Id |
DRUGGABLE GENOME |
ADRA2RL1 | GENE_SYMBOL |
ADRA2B | GENE_SYMBOL |
Alpha-2B adrenergic receptor | UNIPROT |
PA36 | PharmGKB ID |
ADRA2L1 | GO Gene Synonym |
ADRA2RL1 | GO Gene Synonym |
CELL SURFACE, G PROTEIN COUPLED RECEPTOR |
151 | Gene ID |
ADRA2L1 | dGene Synonym |
ADRA2RL1 | dGene Synonym |
G PROTEIN COUPLED RECEPTOR |
ADRA2B | TTD Gene Abbreviation |
T41580 | TTD Target ID |